S3 guideline Atopic dermatitis: Part 2 ‐ Systemic treatment
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2024-02 · 22 (2) · 307-320
DOI: 10.1111/ddg.15229 ↗Kurz gefasst
Leitlinie in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, online erschienen am 31.12.2023. Verfasst von Thomas Werfel und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Allergology and Venereology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Biological Products. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The present S3 guideline was created based on the European English‐language S3 guideline, with special consideration given to the medical conditions in the German‐speaking region, and with additions from the previous German‐language version, in accordance with the criteria of the AWMF. This second part of the guideline addresses the systemic therapy of atopic dermatitis (AD). It covers topics such as the indication for systemic therapy in children, adolescents, and adult patients with AD. Furthermore, it addresses all medications approved for AD, such as the biologics dupilumab and tralokinumab, the Janus kinase inhibitors abrocitinib, baricitinib, and upadacitinib, as well as conventional immunosuppressive therapies with systemic glucocorticosteroids and ciclosporin. Additionally, it discusses systemic off‐label therapies. The first part of the guideline, published separately, includes the definition and diagnostic aspects of AD, describes topical therapy, non‐drug therapy approaches, and addresses aspects related to special patient groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Allergology and Venereology, Hannover Medical School, Hannover, Germany.
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.
- Competence Center for Health Services Research in Dermatology (CVderm), Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Dermatology and Allergology, University Medical Center Munich, Technical University of Munich, Munich, Germany.
- Department of Dermatology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
- Department of Dermatology, Venereology and Allergology, University Hospital Schleswig-Holstein, Campus Kiel, Germany.
Zitieren
APA
Werfel, T., Heratizadeh, A., Aberer, W., Augustin, M., Biedermann, T., Bauer, A., Fölster-Holst, R., Kahle, J., Kinberger, M., Nemat, K., Neustädter, I., Peters, E., von Kiedrowski, R., Schmid-Grendelmeier, P., Schmitt, J., Schwennesen, T., Simon, D., Spindler, T., Traidl-Hoffmann, C., …, & Ott, H. (2024). S3 guideline Atopic dermatitis: Part 2 ‐ Systemic treatment. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 22(2), 307-320. https://doi.org/10.1111/ddg.15229
Vancouver
Werfel T, Heratizadeh A, Aberer W, Augustin M, Biedermann T, Bauer A, et al. S3 guideline Atopic dermatitis: Part 2 ‐ Systemic treatment. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2024;22(2):307-320. doi:10.1111/ddg.15229
BibTeX
@article{Werfel2024,
author = {Werfel, Thomas and Heratizadeh, Annice and Aberer, Werner and Augustin, Matthias and Biedermann, Tilo and Bauer, Andrea and Fölster-Holst, Regina and Kahle, Julia and Kinberger, Maria and Nemat, Katja and Neustädter, Irena and Peters, Eva and von Kiedrowski, Ralph and Schmid-Grendelmeier, Peter and Schmitt, Jochen and Schwennesen, Thomas and Simon, Dagmar and Spindler, Thomas and Traidl-Hoffmann, Claudia and Werner, Ricardo Niklas and Wollenberg, Andreas and Worm, Margitta and Ott, Hagen},
title = {S3 guideline Atopic dermatitis: Part 2 ‐ Systemic treatment},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2024},
volume = {22},
number = {2},
pages = {307--320},
doi = {10.1111/ddg.15229}
}
EUVIMED